BUY Lupin LimitedHSBC Securities

byHSBC SecuritiesHorizon: NA (inferred 1 year)10 Aug 2026via CNBC Awaaz.

Entry₹2,360Inferred
Target₹2,770
Total upside +17.37%
Stop lossNot given
CMP₹2,1102d ago
Active-10.59%+31.28%upside left 11 mo left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 1:36 am IST
43 supporting2 neutral10 opposing
Supports the BUY call (43)

Lupin receives US FDA approval for Modafinil 100 mg, 200 mg tablets

NewsCnbc-Tv18·4 Sept · 2d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Modafinil Tablets, USP.

BSE · Company Update·4 Sept · 2d ago

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Aug · 1w ago

8 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·27 Aug · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.